Streetbeat News

ACON

Aclarion, Inc.

https://www.aclarion.com

Industry

Medical - Healthcare Information Services

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Open

0.12

Mkt cap

1.1M

Volume

1.1M

High

0.12

P/E Ratio

-0.04

52-wk high

7.39

Low

0.10

Div yield

N/A

52-wk low

0.10

Aclarion's Nociscan technology is highlighted in the RSNA edition of Siemens MAGNETOM Flash, showcasing its integration into clinical practices by leading physicians for treating chronic low back pain.

Portfolio Pulse from

November 21, 2024 | 1:15 pm

Aclarion, Inc. (Nasdaq:ACON), a healthcare technology company, will present at the Virtual Investor Summit Microcap Event on November 21st. The company focuses on using biomarkers and AI to help identify chronic low back pain locations.

Portfolio Pulse from

November 14, 2024 | 10:15 pm

In Friday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, Allakos, and Unicycive Therapeutics, while Akanda, Dogwood Therapeutics, and Nexalin Technology were among the losers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 8:31 pm

Aclarion has entered into a $1 million securities purchase agreement, issuing 1,000 Series C preferred shares at $1,000 each. These shares are convertible at $0.1759 per common share, and the agreement includes warrants for 5.7 million common shares.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 8:13 pm

Aclarion has completed the first Nociscan exams for patients in the LIFEHAB trial in Norway. The trial involves 202 patients with chronic low back pain and will compare outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:01 am

Aclarion has filed for a mixed shelf offering of up to $50 million, which allows the company to issue various types of securities over time. This move provides Aclarion with flexibility to raise capital as needed.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:05 am

Aclarion, Inc. (NASDAQ:ACON) has been added to the PRISM Emerging Medical Devices Index, highlighting its innovative AI-driven solutions for chronic low back pain. The company secured its first commercial agreement with Sheridan Community Hospital, marking a significant milestone in its market presence.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 3:29 pm

Top Wall Street analysts have updated their price targets and ratings for several companies. Notable changes include Needham cutting Micron's target to $140, Ascendiant Capital lowering Aclarion's target to $1.5, and Gordon Haskett upgrading Ollie's Bargain Outlet to Buy. Baird raised Foot Locker's target to $35 and Peloton's to $4.75. Loop Capital cut Baidu's target to $115, while JP Morgan upgraded BJ's Wholesale to Neutral. Baird boosted SentinelOne's target to $29, and Wells Fargo upgraded American Homes 4 Rent and Camden Property Trust.

Portfolio Pulse from Avi Kapoor

August 26, 2024 | 12:32 pm

Ascendiant Capital has maintained a Buy rating on Aclarion (NASDAQ:ACON) but has lowered the price target from $1.6 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 9:50 am

Aclarion, Inc. has launched the CLUE Trial to assess how often Nociscan's AI-generated biomarker data influences changes in surgical treatment plans for chronic low back pain. This trial will involve multiple physicians and sites, contributing to Aclarion's clinical evidence.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.